64 related articles for article (PubMed ID: 5428732)
1. Immunity and human malignant melanoma.
Br Med J; 1970 Jun; 2(5712):743-4. PubMed ID: 5428732
[No Abstract] [Full Text] [Related]
2. Malignant melanoma.
Moore GE; Gerner RE
Surg Gynecol Obstet; 1971 Mar; 132(3):427-36. PubMed ID: 5546295
[No Abstract] [Full Text] [Related]
3. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour auto-antibody in human malignant melanoma.
Mansell PW; Verrier-Jones J
J Pathol; 1971 Feb; 103(2):Pxv. PubMed ID: 4936065
[No Abstract] [Full Text] [Related]
5. Autoimmunization with irradiated tumour cells in human malignant melanoma.
Ikonopisov RL; Lewis MG; Hunter-Craig ID; Bodenham DC; Phillips TM; Cooling CI; Proctor J; Fairley GH; Alexander P
Br Med J; 1970 Jun; 2(5712):752-4. PubMed ID: 4913783
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
7. Cell-mediated immunity against malignant melanoma in monozygous twins.
Nagel GA; St Arneault G; Holland JF; Kirkpatrick D; Kirkpatrick R
Cancer Res; 1970 Jun; 30(6):1828-32. PubMed ID: 5466283
[No Abstract] [Full Text] [Related]
8. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.
Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J
Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127
[TBL] [Abstract][Full Text] [Related]
9. Interaction of mononuclear leukocytes with malignant melanoma.
Fujinami N; Zucker-Franklin D; Valentine F
Lab Invest; 1981 Jul; 45(1):28-37. PubMed ID: 7253562
[TBL] [Abstract][Full Text] [Related]
10. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
Gajewski TF; Fallarino F; Ashikari A; Sherman M
Clin Cancer Res; 2001 Mar; 7(3 Suppl):895s-901s. PubMed ID: 11300489
[TBL] [Abstract][Full Text] [Related]
11. In vivo effect and parallel in vitro lymphocyte-mediated tumor cytolysis after Phase I xenogeneic immune RNA treatment of patients with widespread melanoma or metastatic renal cell carcinoma.
Steele G; Wang BS; Richie J; Wilson RE; Ervin T; Yankee R; Fallon M; Mannick JA
Cancer Res; 1980 Jul; 40(7):2377-82. PubMed ID: 6155992
[No Abstract] [Full Text] [Related]
12. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
13. [Basis for a specific-active immunotherapy in malignant melanoma].
Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
[TBL] [Abstract][Full Text] [Related]
14. Regression of malignant melanoma as a manifestation of a cellular immunity response.
Lloyd OC
Proc R Soc Med; 1969 Jun; 62(6):543-5. PubMed ID: 5802725
[No Abstract] [Full Text] [Related]
15. Lyophilized whole human melanoma cells stimulate human PBMC proliferation and enhance suppressive action of PBMC toward survival of the same malignant cell line in vitro.
Juranić ZD; Stanojković TP; Stanojević-Bakić N; Milosević D; Radulović S; Juranić IO
Neoplasma; 1999; 46(4):224-30. PubMed ID: 10613602
[TBL] [Abstract][Full Text] [Related]
16. Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma.
Thomas PJ; Kaur JS; Aitcheson CT; Robinson WA; Tan EM
Cancer Res; 1983 Mar; 43(3):1372-80. PubMed ID: 6337706
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy dispenses with tumor antigens.
Ferrone S
Nat Biotechnol; 2004 Sep; 22(9):1096-8. PubMed ID: 15340476
[No Abstract] [Full Text] [Related]
18. Immunotherapy and immune competence of patients with malignant melanoma.
Kovarík J; Ninger E; Mechl Z; Zemanová D; Lauerová L; Sopková B; Svejda J; Bacovský B; Bártová A; Bártek J
Czech Med; 1983; 6(3):172-4. PubMed ID: 6416794
[No Abstract] [Full Text] [Related]
19. Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF; Fallarino F
Ther Immunol; 1995 Aug; 2(4):211-25. PubMed ID: 9358613
[TBL] [Abstract][Full Text] [Related]
20. The growth of lymphocyte colonies from peripheral blood of patients with malignant melanoma.
Bártková J; Hausner P; Mandys V; Stanová M
Neoplasma; 1984; 31(4):447-52. PubMed ID: 6472515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
